What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

Outlook Therapeutics (NASDAQ:OTLK) Inc has said its chief operations officer Terry Dagnon will discuss the company's wet age-related macular degeneration (AMD) drug Lytenava as part of a panel at the 2022 World Retina Conference later this month.  The conference is taking place from May 12-15, 2022, in Fort Lauderdale, Florida.
mildly positive